Stockscreener 앱 받기
593.87
1.98%
11.53
시간 외 거래:
593.87
전일 마감가:
$582.34
열려 있는:
$582.02
하루 거래량:
281.99K
Relative Volume:
0.85
시가총액:
$13.49B
수익:
-
순이익/손실:
$-518.67M
주가수익비율:
-23.64
EPS:
-25.12
순현금흐름:
$-438.32M
1주 성능:
-0.84%
1개월 성능:
+3.62%
6개월 성능:
+97.86%
1년 성능:
+89.26%
1일 변동 폭
$580.00
$598.79
1주일 범위
$578.00
$599.98
52주 변동 폭
$265.00
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
명칭
Madrigal Pharmaceuticals Inc
전화
404-380-9263
주소
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
MDGL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
593.87 | 13.23B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-11-03 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-09-04 | 재개 | H.C. Wainwright | Buy |
| 2025-02-28 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | 재확인 | H.C. Wainwright | Buy |
| 2024-06-28 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2024-04-22 | 개시 | BofA Securities | Underperform |
| 2024-03-15 | 업그레이드 | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | 개시 | Citigroup | Buy |
| 2024-02-26 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | 재확인 | Oppenheimer | Outperform |
| 2022-12-19 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-19 | 재확인 | Piper Sandler | Overweight |
| 2022-12-19 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-11-24 | 재개 | Evercore ISI | Outperform |
| 2020-11-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-05 | 개시 | BMO Capital Markets | Market Perform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-01-30 | 개시 | Canaccord Genuity | Buy |
| 2020-01-09 | 업그레이드 | UBS | Neutral → Buy |
| 2019-11-07 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-25 | 개시 | Stifel | Hold |
| 2019-06-10 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Outperform |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-12-12 | 개시 | B. Riley FBR | Neutral |
| 2018-11-19 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-09-04 | 개시 | Citigroup | Buy |
| 2018-08-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2018-06-28 | 개시 | Raymond James | Mkt Perform |
모두보기
Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스
Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize - Benzinga
MASH Treatment Market Competition Analysis 2025: How Players Are Shaping Growth - EIN News
(MDGL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Madrigal Pharmaceuticals expands workforce with new equity grants to staff - MSN
Madrigal Pharmaceuticals Earnings Notes - Trefis
Here are the most and least likely M&A targets in biotech, according to Truist - MSN
Madrigal uses equity incentives to lure talent as MASH drug scales up - MSN
What analysts say about Madrigal Pharmaceuticals Inc YDO1 stockLarge Cap Stability Picks & Consistently Superior Profits - earlytimes.in
Madrigal Uses Equity Incentives to Lure Talent as MASH Drug Scales Up - MyChesCo
Madrigal Heads to JPMorgan as MASH Drug Puts Company in the Spotlight - MyChesCo
Madrigal Pharmaceuticals (MDGL) Is Up 5.4% After REZDIFFRA Phase 3 Data And CFO HireHas The Bull Case Changed? - Sahm
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Madrigal Pharmaceuticals stock hits all-time high at 605.86 USD By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals (NASDAQ:MDGL) Reaches New 52-Week HighHere's What Happened - MarketBeat
Madrigal Pharmaceuticals stock hits all-time high at 605.86 USD - Investing.com
Voya Investment Management LLC Grows Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Sagimet rises as licensing deal with Teva unit targets Madrigal drug - MSN
(MDGL) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Bullish Rezdiffra Data, FDA Designations and Analyst Upgrades - Sahm
Trend Report: How strong is Madrigal Pharmaceuticals Inc stock revenue growthQuarterly Profit Review & AI Forecasted Entry and Exit Points - moha.gov.vn
Madrigal Pharmaceuticals Stock Soars as Analysts Raise Price Targets - StocksToTrade
Madrigal Pharmaceuticals Sees Bullish Price Target Increases Amid Market Excitement - timothysykes.com
What consensus target says about Madrigal Pharmaceuticals Inc. (YDO1) stockJuly 2025 Catalysts & Safe Capital Preservation Plans - ulpravda.ru
Madrigal Pharmaceuticals Sees Steady Surge with Revised Analyst Ratings - StocksToTrade
Madrigal Pharmaceuticals Sees Optimistic Price Target Upgrades Amid Expansion Expectations - StocksToTrade
Madrigal Pharmaceuticals’ Stock Surge: Analyzing Latest Price Target Upgrades - timothysykes.com
Madrigal Pharmaceuticals Sees Price Targets Raised Amid Rezdiffra Optimism - timothysykes.com
Madrigal Pharmaceuticals (MDGL): Reassessing Valuation After Strong 1‑Year Share Price Surge - Yahoo Finance
Piper Sandler Raises Price Target for MDGL to $900, Maintains Ov - GuruFocus
Piper Sandler raises Madrigal Pharmaceuticals stock price target to $900 on MASH opportunity - Investing.com UK
Will Madrigal Pharmaceuticals Inc. stock split attract more investorsGDP Growth & Free Community Consensus Stock Picks - DonanımHaber
Piper Sandler Raises Price Target for MDGL to $900, Maintains Overweight Rating | MDGL Stock News - GuruFocus
Will Madrigal Pharmaceuticals Inc. stock outperform value stocksRisk Management & Growth Oriented Trade Recommendations - DonanımHaber
Madrigal Pharmaceuticals price target raised to $900 from $540 at Piper Sandler - TipRanks
Is Madrigal Pharmaceuticals Inc. stock a top momentum playMarket Performance Recap & Long-Term Safe Investment Plans - Улправда
Madrigal Pharmaceuticals Inc (HAM:YDO1) Stock Earnings Transcripts - GuruFocus
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Madrigal Pharmaceuticals (HAM:YDO1) EV-to-OCF : -64.02 (As of Dec. 18, 2025) - GuruFocus
Madrigal Grants New Equity Awards as Hiring Builds Momentum Around MASH Drug - MSN
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Marex Group plc Buys New Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Sells $10,297,597.50 in Stock - MarketBeat
Insider Selling: Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Sells 24,800 Shares of Stock - MarketBeat
Braidwell LP Has $18.40 Million Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Adage Capital Partners GP L.L.C. Buys 184,554 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Taub of Madrigal Pharmaceuticals sells $10.3 million in stock By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals (MDGL) director sells after 24,800-share option - Stock Titan
Madrigal Pharmaceuticals (NASDAQ: MDGL) director discloses 10b5-1 sales, gift - Stock Titan
Madrigal Pharmaceuticals, Inc. $MDGL is Paulson & CO. Inc.'s Largest Position - MarketBeat
Madrigal Pharmaceuticals Inc (MDGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
자본화:
|
볼륨(24시간):